xml version="1.0" encoding="utf-8"?               

   0000310158 false Common Stock ($0.50 par value)        0000310158   2020-02-04 2020-02-05     0000310158  us-gaap:CommonStockMember    2020-02-04 2020-02-05     0000310158  mrk:Sec1.125NotesDue2021Member    2020-02-04 2020-02-05     0000310158  mrk:Sec0.500NotesDue2024Member    2020-02-04 2020-02-05     0000310158  mrk:Sec1.875NotesDue2026Member    2020-02-04 2020-02-05     0000310158  mrk:Sec2.500NotesDue2034Member    2020-02-04 2020-02-05     0000310158  mrk:Sec1.375NotesDue2036Member    2020-02-04 2020-02-05    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of 

the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported) February 5, 2020 

Merck & Co., Inc. 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Registrant’s telephone number, including area code (908) 740-4000 

Not Applicable 

(Former name or former address, if changed since last report.) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ¨ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Item 2.02. Results of Operations and Financial Condition. 

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02. 

Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on February 5, 2020, regarding earnings for the fourth quarter and year end of 2019, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. 

This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. 

Item 8.01. Other Events.  

Incorporated by reference is a press release issued by the Company on February 5, 2020, regarding the spin-off of certain products into a new, independent, publicly-traded company. 

Item 9.01. Financial Statements and Exhibits. 

(d) Exhibits 

   Exhibit 99.1 Press release issued February 5, 2020, regarding earnings for the fourth quarter and year end of 2019 

   Exhibit 99.2 Certain supplemental information not included in the press release 

   Exhibit 99.3 Press release issued February 5, 2020, regarding the spin-off of certain products into a new, independent, publicly-traded company 

   Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED]